
WHAT IS CLAIMED IS:


1. Use of a compound of Formula (I)



(I),

or the pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the treatment of cancer in a subject, wherein the medicament is to be administered to the subject in combination with a monoclonal antibody, wherein said monoclonal antibody is an anti-PD-1 antibody.

2. Use of a compound of Formula (I)



(I),

or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the treatment of cancer in a subject, wherein the medicament is to be administered to the subject in combination with a monoclonal antibody, wherein said monoclonal antibody is an anti-PD-1 antibody.

3. The use of claim 1 or 2, wherein the compound of Formula (I), or the pharmaceutically acceptable salt thereof, is to be administered to the subject in an amount from about 25 mg per day to about 1200 mg per day.

4. The use of claim 3, wherein the compound of Formula (I), or the pharmaceutically acceptable salt thereof, is to be administered to the subject in an amount from about 100 mg per day to about 1200 mg per day.

5. The use of claim 4, wherein the compound of Formula (I), or the pharmaceutically acceptable salt thereof, is to be administered to the subject in an amount from about 200 mg per day to about 1200 mg per day.

6. The use of claim 5, wherein the compound of Formula (I), or the pharmaceutically acceptable salt thereof, is to be administered to the subject in an amount from about 300 mg per day to about 1200 mg per day.

7. The use of claim 6, wherein the compound of Formula (I), or the pharmaceutically acceptable salt thereof, is to be administered to the subject in an amount from about 600 mg per day to about 1200 mg per day.

8. The use of claim 3, wherein the compound of Formula (I), or the pharmaceutically acceptable salt thereof, is to be administered to the subject in an amount from about 25 mg per day to about 600 mg per day.

9. The use of claim 8, wherein the compound of Formula (I), or the pharmaceutically acceptable salt thereof, is to be administered to the subject in an amount from about 100 mg per day to about 600 mg per day.

10. The use of claim 9, wherein the compound of Formula (I), or the pharmaceutically acceptable salt thereof, is to be administered to the subject in an amount from about 200 mg per day to about 600 mg per day.

11. The use of claim 10, wherein the compound of Formula (I), or the pharmaceutically acceptable salt thereof, is to be administered to the subject in an amount from about 300 mg per day to about 600 mg per day.

12. The use of claim 1 or 2, wherein the compound of Formula (I), or the pharmaceutically acceptable salt thereof, is to be administered in doses of 300, and 600 mg either once or twice a day.

13. The use of claim 1 or 2, wherein the cancer is a malignant solid tumor.

14. The use of claim 13, wherein the cancer is metastatic and/or unresectable.

15. The use of claim 14, wherein the cancer is selected from colorectal cancer, pancreatic cancer, liver cancer and lung cancer, or a combination thereof.

16. The use of claim 15, wherein the cancer is colorectal cancer or pancreatic cancer.

17. The use of claim 16, wherein the subject has received at least one prior therapy for the treatment of the cancer.

18. The use of claim 16, wherein the subject is treatment naïve.

19. The use of any one of claims 1 to 18, wherein the monoclonal antibody is nivolumab.

20. The use of claim 19, wherein the nivolumab is to be administered by intravenous infusion at a dose of about 480 mg every 4 weeks.